Assessment of late urinary, bowel and sexual function after dose escalation from 70 to 76 Gy using image-guided radiotherapy in curative treatment of prostate cancer

Scandinavian Journal of Urology and Nephrology

Volumn 46, Issue 2, 2012, Pages 124-132

  Haugnes, Hege S ^a,b   Melby, Bianca ^c   Larsen, Kari M ^a   Langdal, Ingrid ^a   Rasi, Mana ^a   Bremnes, Roy M ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c PW Nilsens Vei 15   (Norway)

Author keywords

Bowel; Image guided; Prostate cancer; Radiotherapy; Sexual; Toxicity; Urinary

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RADIOTHERAPY; COMPARATIVE STUDY; DEVICES; GASTROINTESTINAL TRACT FUNCTION; HUMAN; IMAGE GUIDED RADIOTHERAPY; MAJOR CLINICAL STUDY; MALE; MICTURITION; PRIORITY JOURNAL; PROSTATE CANCER; QUESTIONNAIRE; RADIATION DOSE; RADIATION INJURY; RETROSPECTIVE STUDY; SEXUAL FUNCTION;

ABDOMINAL PAIN; AGED; CHI-SQUARE DISTRIBUTION; CONFIDENCE INTERVALS; DEFECATION; FECAL INCONTINENCE; HUMANS; MALE; MIDDLE AGED; NOCTURIA; ODDS RATIO; PENILE ERECTION; PROSTATIC NEOPLASMS; QUESTIONNAIRES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, IMAGE-GUIDED; RETROSPECTIVE STUDIES; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; STATISTICS, NONPARAMETRIC; TIME FACTORS; URINARY INCONTINENCE; URINATION;

EID: 84858436723     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.3109/00365599.2012.659205     Document Type: Article

References (25)

1. Larsen IK, Grimsrud TK, Haldorsen T, Johannesen TB, Johansen A, Langseth H, et al. Cancer in Norway 2009. Cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2011.
2. Kvale R, Auvinen A, Adami HO, Klint A, Hernes E, Moller B, et al. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst 2007;99:1881-7. (Pubitemid 351767195)
3. Bill-Axelson A, Holmberg L, Filen F, Ruutu M, Garmo H, Busch C, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008; 100:1144-54.
4. Widmark A, Klepp Or, Solberg A, Damber JE, Angelsen A, Fransson P, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009;373:301-8.
5. Walsh PC, DeWeese TL, Eisenberger MA. Clinical practice. Localized prostate cancer. NEngl J Med 2007;357:2696-705.
6. Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007;8:475-87. (Pubitemid 46805903)
7. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67-74. (Pubitemid 350251041)
8. Al-Mamgani A, van Putten WL, Heemsbergen WD, van Leenders GJ, Slot A, Dielwart MF, et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008; 72:980-8.
9. Stephans KL, Xia P, Tendulkar RD, Ciezki JP. The current status of image-guided external beam radiotherapy for prostate cancer. Curr Opin Urol 2010;20:223-8.
10. Fransson P, Bergstrom P, Lofroth PO, Widmark A. Prospective evaluation of urinary and intestinal side effects after BeamCath stereotactic dose-escalated radiotherapy of prostate cancer. Radiother Oncol 2002;63:239-48. (Pubitemid 34874552)
11. Fransson P, Bergstrom P, Lofroth PO, Widmark A. Five-year prospective patient evaluation of bladder and bowel symptoms after dose-escalated radiotherapy for prostate cancer with the BeamCath(R) technique. Int J Radiat Oncol Biol Phys 2006;66:430-8. (Pubitemid 44332735)
12. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000;56:899-905.
13. Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:1124-9. (Pubitemid 351296130)
14. Siglin J, Kubicek GJ, Leiby B, Valicenti RK. Time of decline in sexual function after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010;76: 31-5.
15. Mykletun A, Dahl AA, O'Leary MP, Fossa SD. Assessment of male sexual function by the Brief Sexual Function Inventory. BJU Int 2006;97:316-23.
16. Hanssen S, Norum J. Bladder and rectal toxicity of BeamCath application in radiotherapy of prostate cancer. Anticancer Res 2008;28:2865-8.
17. Fonteyne V, Villeirs G, Lumen N, De Meerleer G. Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancer. Radiother Oncol 2009; 92:42-7.
18. Fransson P, Widmark A. Late side effects unchanged 4-8 years after radiotherapy for prostate carcinoma: a comparison with age-matched controls. Cancer 1999;85: 678-88. (Pubitemid 29075289)
19. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360:103-6.
20. Berg A, Dahl AA, Bruland OS, Bjoro T, Aanensen MS, Fossa SD. Definitive radiotherapy with adjuvant long-term antiandrogen treatment for locally advanced prostate cancer: health-related quality of life and hormonal changes. Prostate Cancer Prostatic Dis 2009;12:269-76.
21. Enzlin P, Mak R, Kittel F, Demyttenaere K. Sexual functioning in a population-based study of men aged 40-69 years: the good news. Int J Impot Res 2004;16:512-20. (Pubitemid 39664859)
22. van der Wielen GJ, Mulhall JP, Incrocci L. Erectile dysfunction after radiotherapy for prostate cancer and radiation dose to the penile structures: a critical review. Radiother Oncol 2007;84:107-13. (Pubitemid 47284535)
23. Teloken PE, Parker M, Mohideen N, Mulhall JP. Predictors of response to sildenafil citrate following radiation therapy for prostate cancer. J Sex Med 2009;6: 1135-40.
24. McNair HA, Parker C, Hansen VN, Askew L, Mukherjee R, Nutting C, et al. An evaluation of BeamCath in the verification process for prostate cancer radiotherapy. Clin Oncol (R Coll Radiol) 2004;16:138-47. (Pubitemid 38344435)
25. Poulsen PR, Fokdal L, Petersen J, Hoyer M. Accuracy of image-guided radiotherapy of prostate cancer based on the BeamCath urethral catheter technique. Radiother Oncol 2007;83:25-30. (Pubitemid 46546444)